跳至主要内容
临床试验/JPRN-UMIN000013204
JPRN-UMIN000013204已完成未知

Randomized control trial of transarterial chemoembolization with miriplatin-lipiodol suspension or drug eluting bead with doxorubicin for hepatocellular carcinoma - Randomized control trial of transarterial chemoembolization with miriplatin-lipiodol suspension or drug eluting bead with doxorubicin for hepatocellular carcinoma

Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan0 个研究点目标入组 56 人开始时间: 2014年5月30日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Having metastasis. 2)Having vascular invasion. 3)Having vascular anormality or AP shunt. 4)Having previous treatment with miriplatin or DC bead. 5)Having previous treatment with sorafenib. 6)Having severe ascites or pleural effusion. 7)Considered as HCC refractory for TACE. 8)Having allergy of contrast agent. 9)Having severe renal failure. 10)Having severe cardiac disease. 11)Having other cancer. 12)Having hemorrhagic varix. 13)Having severe mental disorder. 14)Having severe drug allergy. 15)Having possibility of pregnant or nursing. 16)Deemed inappropriate to perform the study by the physician.

研究者

发起方
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan

相似试验